Chemicon and ASCC Announce Agreement to Commercialize Stem Cell Products
News Apr 24, 2006
Serologicals Corporation and the Australian Stem Cell Centre (ASCC) have announced that they have signed an agreement whereby Chemicon International, Inc., Serologicals’ wholly-owned subsidiary, has obtained exclusive rights to commercialize, market and distribute stem cell reagents developed at the ASCC to scientists all over the world.
Initial products which will be available to researchers through Chemicon include a proprietary stem cell isolation kit, various proteins, and antibodies.
The ASCC is assisting Chemicon in new product development in the research reagent area and expects that other life science tools will also become part of this exclusive research collaboration as they become ready to market.
Chemicon will have the first right of evaluation to commercialize these research reagents developed by the ASCC.
In exchange, Chemicon will make an in-kind contribution of research tools for use by researchers in the ASCC laboratories as well as contribute funds, products and technical expertise to the new stem cell training program recently launched by the ASCC.
"Chemicon is excited to partner with ASCC to bring a vast array of novel stem cell products and technologies to the market," said Jeffrey D. Linton, President of Chemicon and Upstate, which comprise Serologicals’ Research Segment.
"This unique arrangement will benefit stem cell research worldwide by enabling access to the many innovative tools developed at the ASCC which will further accelerate research in this exciting area."
"The Centre has and will continue to develop high-quality research tools through its research programs, which we believe should be available to all scientists to support the development of the entire stem cell industry."
"Chemicon is an ideal partner given its extensive stem cell product portfolio, expertise in international distribution and marketing, and dedication to the realization of the potential of stem cell research."
"In addition to distributing the ASCC’s research reagents, Chemicon is committed to providing novel reagents to our scientists, supporting our training programs, and, most importantly, advancing world-class stem cell research," said Dr Hugh Niall, Chief Executive Officer of the Australian Stem Cell Centre.
About 422 million people around the world, including more than 30 million Americans, have diabetes. Obesity is the most significant risk factor for type 2 diabetes. yet about 30 percent of obese people do not develop type 2 diabetes or other metabolic conditions. New research aims to understand on a cellular level, how this separation occurs.READ MORE